User: A 44-year-old man, a recent immigrant to the United States, presented with a 6-month history of fatigue and an unintentional 7-kg weight loss. He also reported a 2-year history of chronic pain in his hip and chest wall. His presentation was precipitated by acute pain in the right clavicle that occurred after he pushed himself up to a standing position from a chair. He reported no history of fevers, night sweats, dyspnea, or gastrointestinal symptoms. His past medical history was significant for kidney stones, chronic kidney disease, hypertension, and three previous myocardial infarctions. He had a notable family history of renal-cell carcinoma. His current medications included metoprolol, aspirin, and clopidogrel.
On physical examination, the patient appeared in mild distress, supporting his right arm. He was afebrile with a blood pressure of 149/92 mm Hg, a pulse of 67 beats per minute, and an oxygen saturation of 99 percent on room air. Musculoskeletal examination revealed pain, swelling, and deformity over the distal end of the right clavicle, with skin tenting noted over the medial fragment. Cardiovascular, pulmonary, abdominal, and neurologic examinations were unremarkable, and there was no palpable lymphadenopathy. A radiograph of the shoulder confirmed a fracture in the distal third of the right clavicle at the site of a lytic lesion.
Initial laboratory investigations revealed a TLC of 18,300 per microliter with a normal differential count. The hemoglobin level was 16.4 g per deciliter, which later declined to 15.1 g per deciliter after intravenous fluid administration. Kidney function tests showed a blood urea nitrogen of 28 mg per deciliter and a serum creatinine of 2.3 mg per deciliter, which was an elevation from his baseline of 1.8 mg per deciliter. Electrolytes, alanine aminotransferase, and aspartate aminotransferase were within normal limits. The serum calcium level was significantly elevated at 14.3 mg per deciliter with a corrected calcium of 14.5 mg per deciliter. Serum phosphorus was low at 2.5 mg per deciliter. Alkaline phosphatase was elevated at 621 units per liter, while gamma-glutamyltransferase and total protein were normal. Both serum and urine protein electrophoresis showed no evidence of a monoclonal protein.
Hello, Chief Resident here.
Key findings include a pathologic fracture of the right clavicle through a lytic lesion, severe hypercalcemia (14.5 mg/dL), hypophosphatemia, elevated alkaline phosphatase, and chronic kidney disease. The patient’s family history of renal cell carcinoma (RCC) and personal history of nephrolithiasis are critical.
Differential Diagnoses:
1. Primary Hyperparathyroidism (PHPT) with Osteitis Fibrosa Cystica (Brown Tumors): 60%. The combination of severe hypercalcemia, low phosphorus, and multiple lytic lesions (mimicking "brown tumors") in a patient with kidney stones is classic.
2. Parathyroid Carcinoma: 25%. Suggested by the extreme degree of hypercalcemia (>14 mg/dL) and symptomatic bone involvement.
3. Metastatic Renal Cell Carcinoma (Hereditary Syndrome): 10%. Given the family history and lytic lesions, though hypophosphatemia is less typical unless PTHrP-mediated.
4. Multiple Endocrine Neoplasia (MEN1 or 2A): 5%. Explains PHPT and potential associated tumors.
Recommended Next Steps:
1. Serum Intact PTH: To differentiate PTH-mediated from PTHrP-mediated hypercalcemia.
2. PTH-related Protein (PTHrP): To rule out humoral hypercalcemia of malignancy.
3. Sestamibi Scan/Neck Ultrasound: To localize parathyroid pathology.
4. CT Abdomen/Pelvis: To evaluate for RCC or other MEN-associated tumors.
5. Biopsy of the clavicular lesion: If PTH is not diagnostic, to distinguish brown tumor from malignancy.
Hello Attending Consultant here.
Top 3 Differential Diagnoses:
1. Primary hyperparathyroidism with osteitis fibrosa cystica (brown tumor causing pathologic fracture).
2. Parathyroid carcinoma (given extreme hypercalcemia >14 mg/dL, bone disease, and CKD).
3. Humoral hypercalcemia of malignancy (occult RCC or other lytic metastasis, family history).
Suggested Improvements (5 points):
1. Immediately order intact PTH, PTHrP, and 1,25-dihydroxyvitamin D levels.
2. Initiate aggressive IV hydration, calcitonin, and IV bisphosphonate (or denosumab if eGFR <30) for hypercalcemia.
3. Obtain full skeletal survey or bone scan plus neck ultrasound/Sestamibi scan.
4. Perform urgent CT neck/chest/abdomen/pelvis to evaluate for parathyroid mass or occult RCC.
5. Orthopedic consult for clavicle stabilization; avoid biopsy until PTH result available.
6. Genetic counseling for familial RCC syndromes (VHL, HLRCC).
7. Trend ionized calcium, renal function, and ALP; consider cinacalcet if PTH confirmed elevated.
(Word count: 148)
Hello, Expert Clinician here.
Best unifying diagnosis: PTH-mediated hypercalcemia from primary hyperparathyroidism, likely severe and possibly parathyroid carcinoma, with osteitis fibrosa cystica (“brown tumors”) causing multiple lytic lesions and pathologic clavicle fracture.
Why it fits: severe hypercalcemia (14.5), low phosphate, nephrolithiasis/CKD, elevated ALP, chronic bone pain, lytic lesions, negative SPEP/UPEP. This pattern strongly favors PTH excess over myeloma.
Top differentials:
1. Parathyroid adenoma / severe PHPT – best overall fit.
2. Parathyroid carcinoma – consider because calcium is markedly high, skeletal disease is dramatic, and renal involvement is prominent.
3. Metastatic RCC or other malignancy with PTHrP – family history and lytic lesion raise concern, but low phosphate + stones + long bone pain history more strongly suggest endogenous PTH.
4. Multiple myeloma – less likely: normal total protein, negative SPEP/UPEP, low phosphate atypical.
Key pivot: the combination of hypercalcemia + hypophosphatemia + kidney stones + lytic “metastatic-appearing” bone lesions points to hyperparathyroid bone disease.
Most important next move: Measure intact PTH urgently while treating hypercalcemic crisis (aggressive IV saline, calcitonin; antiresorptive therapy with renal-adjusted choice), then localize with neck imaging if PTH is elevated.
Teaching pearl: Brown tumors can mimic metastatic cancer radiographically; phosphate often gives the clue.
User: Further biochemical testing revealed a markedly elevated serum parathyroid hormone level of 4023 pg per milliliter. The 25-hydroxyvitamin D level was 24 ng per milliliter and the 1,25-dihydroxyvitamin D level was 71 pg per milliliter. The parathyroid hormone-related peptide level was within the normal range at 14 pg per milliliter. Chest radiography showed multiple lytic lesions in the ribs and right clavicle along with repeated rib fractures. Computed tomography scans of the chest, abdomen, and pelvis, combined with an FDG-PET scan, identified multiple hypermetabolic lesions in the ribs, right clavicle, and pelvis. A well-circumscribed, mildly FDG-avid anterior mediastinal mass measuring 3.7 cm was also identified. The kidneys were noted to be atrophied and contained multiple nonobstructive stones. An initial technetium-99m-labeled sestamibi scan focused on the neck showed no abnormal trapping.
Hello, Chief Resident here.
The updated findings confirm a PTH-mediated hypercalcemia (PTH 4023 pg/mL) with a 3.7 cm ectopic anterior mediastinal mass. The "lytic lesions" are hypermetabolic on PET, which, in the context of extreme PTH elevation and low phosphorus, are diagnostic of osteitis fibrosa cystica (brown tumors) rather than malignancy. The negative neck sestamibi scan is explained by the ectopic mediastinal location.
Differential Diagnoses:
1. Ectopic Parathyroid Carcinoma: 65%. The PTH level (>10x upper limit), severe hypercalcemia, and large mediastinal mass size (3.7 cm) are highly suspicious for malignancy.
2. Ectopic Parathyroid Adenoma: 30%. While more common, the biochemical severity is atypical for a simple adenoma.
3. Primary Hyperparathyroidism in MEN1/2A: 5%. Must be considered given the family history of RCC (potential VHL or MEN overlap).
Recommended Next Steps:
1. Surgical Oncology/Thoracic Consultation: For resection of the mediastinal mass (definitive diagnosis and treatment).
2. Cine-CT or Targeted Mediastinal Imaging: To better define surgical planes.
3. Aggressive Pre-operative Management: Continue IV fluids and consider Cinacalcet to lower calcium before surgery.
4. Monitor for Hungry Bone Syndrome: Post-operative calcium and phosphorus monitoring will be critical.
Hello Attending Consultant here.
Top 3 Differential Diagnoses:
1. Ectopic mediastinal parathyroid carcinoma (PTH 4023 pg/mL, 3.7-cm mass, extreme hypercalcemia, brown tumors).
2. Ectopic parathyroid adenoma with osteitis fibrosa cystica.
3. Occult metastatic RCC with paraneoplastic PTHrP (unlikely given suppressed PTHrP and markedly elevated intact PTH).
Suggested Improvements:
1. Urgent thoracic surgery consult for en-bloc mediastinal mass resection.
2. Pre-op optimization: aggressive IV saline + calcitonin + denosumab (given CKD); consider cinacalcet bridge.
3. 4D-CT or choline-PET for precise localization if sestamibi remains negative.
4. Intraoperative PTH monitoring and frozen section to confirm parathyroid origin.
5. Post-op monitoring for hungry-bone syndrome with IV calcium, vitamin D, and phosphate repletion.
6. Genetic testing (CDC73, MEN1, VHL) given family RCC history and young age.
7. Orthopedic stabilization of clavicle fracture; avoid biopsy.
(Word count: 138)
Hello, Expert Clinician here.
Best diagnosis: Ectopic mediastinal primary hyperparathyroidism, most concerning for parathyroid carcinoma (vs giant ectopic adenoma), causing osteitis fibrosa cystica/brown tumors with pathologic fractures.
Why: PTH 4023 pg/mL is massively elevated; hypercalcemia is severe; phosphorus is low; nephrolithiasis/CKD, high ALP, and multiple lytic hypermetabolic bone lesions are classic for advanced hyperparathyroid bone disease. Normal PTHrP essentially excludes humoral malignancy. Negative neck sestamibi plus an anterior mediastinal mass strongly suggests an ectopic parathyroid lesion.
Differentials:
1. Ectopic parathyroid carcinoma — favored by very high PTH, marked calcium elevation, 3.7-cm mass, severe skeletal/renal disease.
2. Ectopic parathyroid adenoma — possible; ectopic adenomas can be mediastinal, but biochemical severity is less typical.
3. RCC/metastatic malignancy — much less likely now; would not explain extreme intact PTH elevation.
Key pivot: The case flips from “metastatic lytic cancer” to PTH-driven bone disease once the PTH returns profoundly elevated.
Most important next move: Urgent localization and definitive surgical planning for mediastinal resection (thoracic/endocrine surgery), while controlling calcium aggressively and preparing for post-op hungry bone syndrome.
Teaching pearl: Brown tumors are FDG-avid and can closely mimic metastatic cancer.
User: The patient was treated for severe hypercalcemia with intravenous isotonic normal saline and 4 mg of zoledronic acid. After three days, his corrected calcium level decreased to 10 mg per deciliter and his creatinine improved to 1.9 mg per deciliter. A biopsy of the lytic lesion in the right clavicle was performed, which revealed multinucleated giant cells in a fibrous background with hemosiderin deposition and interstitial hemorrhage. These findings were consistent with a brown tumor, and no malignant cells were identified. A repeat sestamibi scan that included the chest confirmed avid isotope localization within the previously identified mediastinal mass, suggesting an ectopic, hyperfunctioning parathyroid gland.
Hello, Chief Resident here.
Key Findings:
The biopsy confirms brown tumors (osteitis fibrosa cystica), ruling out metastatic malignancy. The repeat sestamibi scan localizes the source to the 3.7 cm ectopic mediastinal mass. The biochemical profile (PTH >4000 pg/mL) remains the most striking feature.
Differential Diagnoses:
1. Ectopic Parathyroid Carcinoma: 75%. The extreme PTH elevation, large size of the ectopic mass, and severity of bone disease are hallmarks of carcinoma.
2. Ectopic Giant Parathyroid Adenoma: 20%. While histologically benign, "giant" adenomas can cause profound biochemical shifts but are less common at this PTH magnitude.
3. Atypical Parathyroid Adenoma: 5%. Lesions with some features of malignancy but lacking clear capsular or vascular invasion.
Recommended Next Steps:
1. Surgical Resection: Urgent referral to Thoracic Surgery for en-bloc resection of the mediastinal mass.
2. Intraoperative PTH Monitoring: To confirm a >50% drop, ensuring the ectopic source was the sole driver.
3. Aggressive Post-operative Monitoring: High risk for Hungry Bone Syndrome; anticipate the need for IV calcium gluconate and high-dose calcitriol.
4. Genetic Testing: Specifically for the CDC73 (HRPT2) mutation, given the suspicion of parathyroid carcinoma and family history of RCC.
Hello Attending Consultant here.
Top 3 Differential Diagnoses:
1. Ectopic mediastinal parathyroid carcinoma (extreme PTH 4023 pg/mL, 3.7-cm mass, brown tumors).
2. Ectopic giant parathyroid adenoma with osteitis fibrosa cystica.
3. Atypical parathyroid neoplasm (borderline malignant features).
Suggested Improvements:
1. Urgent thoracic/endocrine surgery consult for en-bloc mediastinal resection.
2. Intraoperative PTH assay to confirm biochemical cure.
3. Pre-op cinacalcet if calcium rebounds; continue denosumab given CKD.
4. Post-op protocol for hungry-bone syndrome (IV calcium, calcitriol, phosphate).
5. Genetic testing (CDC73, MEN1, VHL) due to family RCC history.
6. Orthopedic fixation of clavicle fracture.
7. Avoid further biopsy; brown-tumor histology is now diagnostic.
(Word count: 112)
Hello, Expert Clinician here.
Best unifying diagnosis: Ectopic mediastinal parathyroid neoplasm causing severe primary hyperparathyroidism with osteitis fibrosa cystica (brown tumors); parathyroid carcinoma is strongly favored over giant adenoma.
Why it fits: Massive PTH 4023 pg/mL, severe hypercalcemia, low phosphate, nephrolithiasis/CKD, high ALP, biopsy-proven brown tumor, and sestamibi uptake in a 3.7-cm anterior mediastinal mass. This explains the lytic lesions and pathologic clavicle fracture without invoking metastatic cancer.
Top differentials:
1. Parathyroid carcinoma — favored by very high PTH/calcium, large ectopic mass, severe bone/renal disease.
2. Giant ectopic parathyroid adenoma — possible, but biochemical and end-organ severity are less typical.
3. Atypical parathyroid tumor — pathology may ultimately fall here if invasion/metastasis is absent.
Key pivot: The biopsy showing brown tumor plus chest-inclusive sestamibi localization definitively reframed “widely metastatic lytic disease” as advanced hyperparathyroid bone disease.
Most important next move: Definitive surgical resection by experienced thoracic/endocrine surgeons, ideally en bloc if carcinoma suspected, with perioperative calcium control and close postoperative monitoring for hungry bone syndrome.
Teaching pearl: In severe PHPT, FDG-avid lytic lesions are not necessarily metastases—brown tumors can closely mimic cancer.
User: The patient was referred to cardiothoracic surgery for resection of the mediastinal mass. During the procedure, the parathyroid hormone level dropped from 4166 to 261 pg per milliliter, and further declined to 87 pg per milliliter by postoperative day five. His recovery was complicated by profound and prolonged hypocalcemia consistent with hungry bone syndrome, requiring intravenous calcium infusion and high doses of calcitriol and cholecalciferol. Pathological analysis of the 2.5 cm encapsulated mass revealed a hypercellular parathyroid tumor with cellular atypia and nests of small tumors within the fibrous capsule. Immunohistochemical staining was positive for parathyroid hormone, cytokeratin, and chromogranin, with a Ki-67 proliferation index of 7 percent. The final diagnosis was ectopic parathyroid carcinoma. Five years later, the patient experienced a recurrence with an increasing parathyroid hormone level and a new 1.3 cm mediastinal lesion before being lost to follow-up.
Hello, Chief Resident here.
Key Findings:
The case concludes with the surgical resection of a 2.5 cm mediastinal mass, confirming ectopic parathyroid carcinoma. Key diagnostic indicators were the massive PTH elevation (4166 pg/mL), severe hypercalcemia, and biopsy-proven brown tumors. The postoperative course was marked by Hungry Bone Syndrome, a common complication when chronic, severe PTH-driven bone resorption is abruptly halted.
Final Diagnosis & Reasoning:
1. Ectopic Parathyroid Carcinoma (100%): Confirmed by histopathology (capsular nesting, cellular atypia, Ki-67 of 7%) and clinical recurrence five years later. The ectopic location (mediastinum) and extreme biochemical profile are classic for this rare malignancy.
Management Analysis:
* Hungry Bone Syndrome: The profound hypocalcemia required aggressive replacement, highlighting the need for pre-operative recognition of high-risk patients (high ALP, large tumors).
* Recurrence: Parathyroid carcinoma has a high recurrence rate (up to 50%). The new mediastinal lesion and rising PTH confirm the aggressive nature of this tumor.
Teaching Pearl: In patients with "metastatic" lytic lesions and hypercalcemia, always check intact PTH and Phosphorus. A low phosphorus level should immediately shift the differential from malignancy to primary hyperparathyroidism.
Hello Attending Consultant here.
Top 3 Differential Diagnoses:
1. Ectopic parathyroid carcinoma (confirmed).
2. Giant ectopic parathyroid adenoma (histologically excluded).
3. Recurrent/metastatic parathyroid carcinoma (5-yr mediastinal relapse).
Suggested Improvements:
1. Pre-op risk-stratify for hungry-bone syndrome (high ALP, PTH >1000, large tumor).
2. Use intraoperative PTH monitoring (already done; target >50% drop).
3. Plan en-bloc resection with margins for suspected carcinoma.
4. Post-op: protocolized IV calcium, calcitriol, phosphate repletion; monitor ionized Ca q6h.
5. Lifelong surveillance with PTH, calcium, neck/chest CT every 6 mo given 30-50% recurrence rate.
6. Genetic testing (CDC73/HRPT2) for germline mutation and family counseling.
7. Avoid bisphosphonates if hungry-bone risk is very high; prefer denosumab in CKD.
(Word count: 118)
Hello, Expert Clinician here.
Final unifying diagnosis: Ectopic mediastinal parathyroid carcinoma causing severe primary hyperparathyroidism with osteitis fibrosa cystica/brown tumors, pathologic fracture, nephrolithiasis/CKD, and postoperative hungry bone syndrome.
Why it fits: Extreme PTH (>4000), severe hypercalcemia with low phosphate, biopsy-proven brown tumor, sestamibi-localized mediastinal lesion, intraoperative PTH collapse, pathology showing atypia/capsular tumor nests, and later biochemical/radiographic recurrence.
Top differentials considered earlier:
1. Giant ectopic parathyroid adenoma — plausible initially, but recurrence and carcinoma pathology argue against.
2. Atypical parathyroid neoplasm — overlap histologically, but clinical recurrence supports carcinoma.
3. Metastatic malignancy/RCC/myeloma — excluded by PTH biology and brown-tumor histology.
Key pivot: The decisive turn was recognizing that “metastatic” lytic lesions plus kidney stones and low phosphate indicated PTH-driven bone disease, not primary skeletal metastases.
Most important next move now: Lifelong surveillance for recurrent disease: serial calcium/PTH and periodic chest/mediastinal imaging; resect localized recurrence when feasible, with cinacalcet for biochemical control if unresectable.
Teaching pearl: In parathyroid carcinoma, recurrence may occur years later despite initial biochemical cure—follow-up must be indefinite.